ArticlesManagement of Radiation Toxicity in Head and Neck Cancers☆
Introduction
The incidence of head and neck cancers (HNC) in the United States is approximately 62,000 cases diagnosed per year.1 Worldwide, the incidence is more than 10 times this number with approximately 686,000 new cases.2 Radiation therapy (RT) plays an essential role in the definitive, postoperative and palliative treatment of HNC. However, RT is associated with significant side effects during and after the completion of therapy. This review examines some of the commonly noted toxicities of RT and their management strategies. The list below excludes concurrent chemotherapy-related acute and late side effects such as nausea, vomiting, nephrotoxicity, and ototoxicity.
Section snippets
Mucositis
Mucositis is a condition characterized by inflammation of the oral mucosa resulting in pain and burning sensation with consequent compromised oral intake in patients with HNC undergoing RT. Patient-related factors that contribute to the development and severity of mucositis include poor orodental hygiene, smoking, alcohol intake, and consuming hot and spicy foods.
Mucositis is a very common side effect seen in 90%-100% of patients undergoing RT alone or with concurrent chemotherapy. Trotti et al3
Xerostomia
Xerostomia is the sensation of dryness in the mouth and is a very common and significant complaint in patients undergoing head and neck (H&N) RT. It is an acute symptom starting as early as the second week of RT and persists as a subacute and late side effect of treatment. Patients complain of dry mouth and thick sticky saliva that is difficult to swallow or spit out. This causes significant discomfort with feelings of gagging and nausea. IMRT has resulted in a significant improvement in
Dysgeusia
Dysgeusia refers to the altered taste or lack of taste experienced by patients undergoing H&N RT. Loss of taste precedes the development of mucositis or clinically significant xerostomia. It usually starts around a dose of 10-16 Gy and taste is almost completely lost by 24-30 Gy. The combined effect of dry mouth, taste changes, and pain due to mucositis results in reduced oral intake, weight loss, and reduced QOL. In patients receiving concurrent chemotherapy these symptoms are further
Dermatitis
Radiation-induced skin reactions are seen in up to 95% of patients.41 These can be in the form of redness (erythema), pain or burning sensation on the skin, and dry or moist desquamation. The use of high-energy megavoltage radiation reduced the rate of skin reactions as compared to cobalt-60 treatment. However, the use of IMRT techniques can result in increased skin dose due to the tangential incidence of beams on the skin.42 Radiation reactions on the skin typically parallel the development of
Radiation Caries and Osteoradionecrosis
Radiation caries refers to tooth decay or breakdown of teeth that can occur because of RT. This is a rapidly progressing condition that can involve the dental pulp resulting in the loss of involved teeth. One of the major contributing factors is RT-induced xerostomia. Because of radiation to the salivary glands, the composition of the saliva changes and becomes thick and sticky and the pH changes from 7.0 to 5.0.52 This results in reduced buffering capacity of the saliva and makes it more
Dysphagia
Radiation-induced dysphagia is a significant radiation toxicity resulting in difficulty in swallowing during the oral, pharyngeal, or esophageal phases of swallowing. It may be associated with overt or silent aspiration. Some patients may present with dysphagia at the outset because of tumor involvement of the swallowing structures. This condition should not be classified as a radiation-related complication.
This RT-related complication has recently received significant attention in literature
QOL Implications
So far, the focus of this review has been on the management of toxicities, primarily as documented by physicians or other healthcare providers. Indeed, for decades, the classic approach for reporting toxicities in oncology has been through the National Cancer Institute׳s Common Terminology Criteria for Adverse Events (CTCAE). Of note, approximately 10% of the ~800 items on this list represent symptoms, such as fatigue or nausea. However, studies have shown that clinicians tend to underreport
Conclusion
RT for HNC is associated with significant acute and late side effects with a consequent impact on patient QOL. The use of new technologies and novel approaches such as IMRT and adaptive RT has demonstrated the potential to alleviate or minimize some of these side effects. Detailed investigations into the impact of these measures on PROs and QOL will allow constant modulation and improvement in physical and biological means to reduce or treat these side effects.
References (83)
- et al.
Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review
Radiother Oncol
(2003) - et al.
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer
Int J Radiat Oncol Biol Phys
(2012) - et al.
Management of somatic pain induced by head and neck cancer treatment: Pain following radiation therapy and chemotherapy. Guidelines of the French Otorhinolaryngology Head and Neck Surgery Society (SFORL)
Eur Ann Otorhinolaryngol Head Neck Dis
(2014) - et al.
Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements
Crit Rev Oncol Hematol
(2016) - et al.
Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients—A triple blinded randomized controlled trial
Radiother Oncol
(2012) - et al.
Adaptive radiotherapy for head and neck cancer--dosimetric results from a prospective clinical trial
Radiother Oncol
(2013) - et al.
Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer
Int J Radiat Oncol Biol Phys
(2006) - et al.
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: Successes and barriers
Int J Radiat Oncol Biol Phys
(2010) - et al.
Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis
J Am Dent Assoc
(2016) - et al.
Is pilocarpine effective in preventing radiation-induced xerostomia? A systematic review and meta-analysis
Int J Radiat Oncol Biol Phys
(2016)
Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer
Int J Radiat Oncol Biol Phys
Acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating radiation-induced xerostomia: Results of RTOG 0537 phase 3 study
Int J Radiat Oncol Biol Phys
Xerostomia: Current streams of investigation
Oral Surg Oral Med Oral Pathol Oral Radiol
De Gustibus: Time scale of loss and recovery of tastes caused by radiotherapy
Radiother Oncol
Treatment-related dysgeusia in head and neck cancer patients
Cancer Treat Rev
Predictors of dysgeusia in patients with oropharyngeal cancer treated with chemotherapy and intensity modulated radiation therapy
Int J Radiat Oncol Biol Phys
Relation between acute and late irradiation impairment of four basic tastes and irradiated tongue volume in patients with head-and-neck cancer
Int J Radiat Oncol Biol Phys
Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)
Int J Radiat Oncol Biol Phys
Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus
Crit Rev Oncol Hematol
Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma
Int J Radiat Oncol Biol Phys
Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer
Breast
Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: A double-blind, randomized study
Int J Radiat Oncol Biol Phys
Prophylactic effect of pentoxifylline on radiotherapy complications: A clinical study
Otolaryngol Head Neck Surg
Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Proposals for a revised grading system and consensus management guidelines
Ann Oncol
The management of osteoradionecrosis of the jaws—A review
Surgeon
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement
Crit Rev Oncol Hematol
Conservative management of osteoradionecrosis
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
Osteoradionecrosis and intensity modulated radiation therapy: An overview
Crit Rev Oncol Hematol
Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: Likely contributions of both dental care and improved dose distributions
Int J Radiat Oncol Biol Phys
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: An update of the Memorial Sloan-Kettering Cancer Center experience
Int J Radiat Oncol Biol Phys
Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer
Int J Radiat Oncol Biol Phys
Prevention of osteoradionecrosis: A randomized prospective clinical trial of hyperbaric oxygen versus penicillin
J Am Dent Assoc
Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): A phase II trial
Int J Radiat Oncol Biol Phys
Delineation of organs at risk involved in swallowing for radiotherapy treatment planning
Radiother Oncol
Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus
Crit Rev Oncol Hematol
Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation
Eur J Cancer
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial
Lancet Oncol
Cancer statistics, 2016
CA Cancer J Clin
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Int J Cancer
Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy
Head Neck
Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial
Cancer
Cited by (68)
Cluster-based radiomics reveal spatial heterogeneity of bevacizumab response for treatment of radiotherapy-induced cerebral necrosis
2024, Computational and Structural Biotechnology JournalEnabling ultra-high dose rate electron beams at a clinical linear accelerator for isocentric treatments
2023, Radiotherapy and OncologyLeveraging nano-engineered mesenchymal stem cells for intramedullary spinal cord tumor treatment
2023, Chinese Chemical LettersForked Paramedian forehead flap combined with nasolabial flap for pre-radiation coverage of exposed maxilla in the Total Rhinectomy patient
2023, American Journal of Otolaryngology - Head and Neck Medicine and SurgeryWhat Special Considerations Are Needed in Patients With Head and Neck Cancer?
2023, Evidence-Based Practice of Palliative Medicine, Second Edition
- ☆
Conflict of interest: The authors report no conflict of interest pertaining to any of the material presented in this manuscript.